Latest & greatest articles for metformin

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on metformin or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on metformin and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for metformin

62. Metformin Use in Patients with Historical Contraindications or Precautions

Metformin Use in Patients with Historical Contraindications or Precautions 4 Department of Veterans Affairs Health Services Research & Development Service Evidence-based Synthesis Program Metformin Use in Patients with Contraindications or Precautions September 2016 Prepared for: Department of Veterans Affairs Veterans Health Administration Quality Enhancement Research Initiative Health Services Research & Development Service Washington, DC 20420 Prepared by: Evidence-based Synthesis Program (...) Affairs and should not be distributed outside the agency. Metformin Use in Patients with Contraindications or Precautions Evidence-based Synthesis Program i PREFACE The VA Evidence-based Synthesis Program (ESP) was established in 2007 to provide timely and accurate syntheses of targeted healthcare topics of particular importance to clinicians, managers, and policymakers as they work to improve the health and healthcare of Veterans. QUERI provides funding for four ESP Centers, and each Center has

Veterans Affairs Evidence-based Synthesis Program Reports2017

63. Metformin decreases progerin expression and alleviates pathological defects of Hutchinson–Gilford progeria syndrome cells

Metformin decreases progerin expression and alleviates pathological defects of Hutchinson–Gilford progeria syndrome cells 28721276 2018 11 13 2056-3973 2 2016 NPJ aging and mechanisms of disease NPJ Aging Mech Dis Metformin decreases progerin expression and alleviates pathological defects of Hutchinson-Gilford progeria syndrome cells. 16026 10.1038/npjamd.2016.26 Hutchinson-Gilford progeria syndrome (HGPS) is a rare genetic disorder that causes systemic accelerated aging in children (...) . This syndrome is due to a mutation in the LMNA gene that leads to the production of a truncated and toxic form of lamin A called progerin. Because the balance between the A-type lamins is controlled by the RNA-binding protein SRSF1, we have hypothesized that its inhibition may have therapeutic effects for HGPS. For this purpose, we evaluated the antidiabetic drug metformin and demonstrated that 48 h treatment with 5 mmol/l metformin decreases SRSF1 and progerin expression in mesenchymal stem cells derived

NPJ aging and mechanisms of disease2016 Full Text: Link to full Text with Trip Pro

64. Metformin Use in Patients with Historical Contraindications or Precautions

Metformin Use in Patients with Historical Contraindications or Precautions Management Briefs Search the HSR&D website Button to search HSRD ® Inside VA Budget and Performance Inside the News Room National Observances Special Events » » » » » Management Briefs Health Services Research & Development Management Brief no. 116 » Issue 116 October 2016 The systematic review reported on here is a product of the VA/HSR&D Quality Enhancement Research Initiative (QUERI) Evidence-Based Synthesis Program (...) . Metformin Use in Patients with Historical Contraindications or Precautions Metformin is an oral hypoglycemic medication used primarily for treating type 2 diabetes mellitus. Evidence suggests that in addition to improving glycemic control, metformin may be associated with improved all-cause and cardiovascular mortality and decreased risk of some cancers. However, clinicians have traditionally been advised by the U.S. Food and Drug Administration (FDA) to exercise caution in prescribing metformin

Veterans Affairs - R&D2016

65. Efficacy and safety of initial combination therapy with gemigliptin and metformin compared with monotherapy with either drug in patients with type 2 diabetes: A double-blind randomized controlled trial (INICOM study)

Efficacy and safety of initial combination therapy with gemigliptin and metformin compared with monotherapy with either drug in patients with type 2 diabetes: A double-blind randomized controlled trial (INICOM study) 27619558 2016 09 13 2016 12 23 1463-1326 19 1 2017 Jan Diabetes, obesity & metabolism Diabetes Obes Metab Efficacy and safety of initial combination therapy with gemigliptin and metformin compared with monotherapy with either drug in patients with type 2 diabetes: A double-blind (...) randomized controlled trial (INICOM study). 87-97 10.1111/dom.12787 Gemigliptin is a new dipeptidyl peptidase-IV inhibitor. We investigated the efficacy and safety of initial combination therapy with gemigliptin and metformin compared with monotherapy with either drug in patients with type 2 diabetes (T2D). A total of 433 T2D patients with a glycosylated haemoglobin (HbA1c) level of 7.5% to 11.0% and a fasting plasma glucose (FPG) concentration <270 mg/dL were randomly assigned to 3 groups: (1

EvidenceUpdates2016

66. [Empagliflozin/metformin]

[Empagliflozin/metformin] Empagliflozin/metformin (diabetes mellitus Typ 2): addendum zum auftrag A16-13; auftrag A16-47 [Empagliflozin/metformin - addendum to commission A16-13] Empagliflozin/metformin (diabetes mellitus Typ 2): addendum zum auftrag A16-13; auftrag A16-47 [Empagliflozin/metformin - addendum to commission A16-13] Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) Record Status This is a bibliographic record of a published health technology assessment from (...) a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG). Empagliflozin/metformin (diabetes mellitus Typ 2): addendum zum auftrag A16-13; auftrag A16-47. [Empagliflozin/metformin - addendum to commission A16-13] Cologne: Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG). IQWiG-Berichte 418. 2016 Final publication URL Indexing Status Subject indexing

Health Technology Assessment (HTA) Database.2016

67. Use of metformin to treat diabetes now expanded to patients with moderately reduced kidney function

Use of metformin to treat diabetes now expanded to patients with moderately reduced kidney function European Medicines Agency - - Use of metformin to treat diabetes now expanded to patients with moderately reduced kidney function Search for medicines Main navigation Use of metformin to treat diabetes now expanded to patients with moderately reduced kidney function Press release 14/10/2016 Use of metformin to treat diabetes now expanded to patients with moderately reduced kidney function (...) Recommendations for patients with kidney impairment updated in product information The European Medicines Agency (EMA) has concluded that metformin-containing medicines can now be used in patients with moderately reduced kidney function (GFR [glomerular filtration rate]=30–59 ml/min) for the treatment of type 2 diabetes. The product information for these medicines will be updated to revise the current contraindication and give information about doses, monitoring and precautions in patients with reduced kidney

European Medicines Agency - EPARs2016

68. Does metformin reduce excess birthweight in offspring of obese pregnant women? A randomised controlled trial of efficacy, exploration of mechanisms and evaluation of other pregnancy complications

Does metformin reduce excess birthweight in offspring of obese pregnant women? A randomised controlled trial of efficacy, exploration of mechanisms and evaluation of other pregnancy complications Does metformin reduce excess birthweight in offspring of obese pregnant women? A randomised controlled trial of efficacy, exploration of mechanisms and evaluation of other pregnancy complications Journals Library An error occurred retrieving content to display, please try again. >> >> >> Page Not Found (...) Page not found (404) Sorry - the page you requested could not be found. Please choose a page from the navigation or try a website search above to find the information you need. >> >> >> >> Issue {{metadata .Issue }} Toolkit 1)"> 0)"> {{metadata.Title}} {{metadata.Headline}} Metformin taken by obese pregnant women did not reduce their baby’s birthweight. {{author}} {{($index , , , , , , , , , , , , , , , , , , , , , & . Carolyn A Chiswick, 1 Rebecca M Reynolds, 2 Fiona C Denison, 1 Amanda J Drake, 2

NIHR HTA programme2016 Full Text: Link to full Text with Trip Pro

69. [Empagliflozin/metformin: benefit assessment according to õ35a Social Code Book V]

[Empagliflozin/metformin: benefit assessment according to õ35a Social Code Book V] Empagliflozin/Metformin: nutzenbewertung gemäß § 35a SGB V; dossierbewertung; auftrag A16-1 [Empagliflozin/metformin: benefit assessment according to §35a Social Code Book V] Empagliflozin/Metformin: nutzenbewertung gemäß § 35a SGB V; dossierbewertung; auftrag A16-1 [Empagliflozin/metformin: benefit assessment according to §35a Social Code Book V] Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (...) Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen. Empagliflozin/Metformin: nutzenbewertung gemäß § 35a SGB V; dossierbewertung; auftrag A16-1. [Empagliflozin/metformin: benefit assessment according to §35a Social Code Book V] Cologne: Institut fuer Qualitaet und Wirtschaftlichkeit

Health Technology Assessment (HTA) Database.2016

70. Cardiovascular safety of glucose-lowering agents as add-on medication to metformin treatment in type 2 diabetes: report from the Swedish National Diabetes Register

Cardiovascular safety of glucose-lowering agents as add-on medication to metformin treatment in type 2 diabetes: report from the Swedish National Diabetes Register 27282621 2016 09 14 2016 09 14 1463-1326 18 10 2016 Oct Diabetes, obesity & metabolism Diabetes Obes Metab Cardiovascular safety of glucose-lowering agents as add-on medication to metformin treatment in type 2 diabetes: report from the Swedish National Diabetes Register. 990-8 10.1111/dom.12704 To investigate the relative safety (...) of various glucose-lowering agents as add-on medication to metformin in type 2 diabetes in an observational study linking five national health registers. Patients with type 2 diabetes who had been on metformin monotherapy and started another agent in addition to metformin were eligible for inclusion. The study period was 2005-2012. Adjusted hazard ratios (HRs) with 95% confidence intervals (CIs) of mortality, cardiovascular disease (CVD), coronary heart disease (CHD), stroke and congestive heart

EvidenceUpdates2016

71. Efficacy and safety of combination therapy with vildagliptin and metformin versus metformin uptitration in Chinese patients with type 2 diabetes inadequately controlled with metformin monotherapy: a randomized, open-label, prospective study (VISION)

Efficacy and safety of combination therapy with vildagliptin and metformin versus metformin uptitration in Chinese patients with type 2 diabetes inadequately controlled with metformin monotherapy: a randomized, open-label, prospective study (VISION) 27406394 2016 07 13 2016 07 13 1463-1326 18 8 2016 Aug Diabetes, obesity & metabolism Diabetes Obes Metab Efficacy and safety of combination therapy with vildagliptin and metformin versus metformin uptitration in Chinese patients (...) with type 2 diabetes inadequately controlled with metformin monotherapy: a randomized, open-label, prospective study (VISION). 775-82 10.1111/dom.12667 To compare the efficacy and safety of combination of vildagliptin and metformin therapy with metformin uptitration in Chinese patients with type 2 diabetes (T2DM) inadequately controlled with low-dose metformin. In this 24-week prospective, randomized, multicentre, open-label study, patients with T2DM inadequately controlled with metformin ≤1000 mg daily were

EvidenceUpdates2016

72. Glucose Control in Severely Burned Patients Using Metformin: An Interim Safety and Efficacy Analysis of a Phase II Randomized Controlled Trial

Glucose Control in Severely Burned Patients Using Metformin: An Interim Safety and Efficacy Analysis of a Phase II Randomized Controlled Trial 27355267 2016 08 12 2016 08 12 1528-1140 264 3 2016 Sep Annals of surgery Ann. Surg. Glucose Control in Severely Burned Patients Using Metformin: An Interim Safety and Efficacy Analysis of a Phase II Randomized Controlled Trial. 518-27 10.1097/SLA.0000000000001845 To determine whether metformin can achieve glucose control no worse than insulin (...) (noninferiority) without the danger of hypoglycemia (superiority). In addition, to assess whether metformin has any additional effects on lipolysis and inflammation that will enhance burn recovery (superiority). Hyperglycemia and insulin resistance after burn injury are associated with increased morbidity and mortality. Insulin administration improves postburn infections, severity of sepsis, and morbidity, but also causes a 4-5-fold increase in hypoglycemia, which is associated with a 9-fold increase

EvidenceUpdates2016

73. Risk of hypoglycaemia in users of sulphonylureas compared with metformin in relation to renal function and sulphonylurea metabolite group: population based cohort study.

Risk of hypoglycaemia in users of sulphonylureas compared with metformin in relation to renal function and sulphonylurea metabolite group: population based cohort study. OBJECTIVE: To determine the association between use of sulphonylureas and risk of hypoglycaemia in relation to renal function and sulphonylurea metabolic group compared with use of metformin. DESIGN: Population based cohort study using routinely collected data from general practices in England. SETTING: Clinical Practice (...) determined using Cox proportional hazard models. Adjustments were made for age, sex, lifestyle, comorbidity, and drug use. RESULTS: The risk of hypoglycaemia in current users of sulphonylureas only was significantly increased compared with current users of metformin only (adjusted hazard ratio 2.50, 95% confidence interval 2.23 to 2.82). The higher risk in current users of sulphonylureas only was further increased in patients with an estimated glomerular filtration rate of less than 30 mL/min/1.73 m(2

BMJ2016 Full Text: Link to full Text with Trip Pro

74. XIGDUO (dapagliflozin/metformin), antidiabetic - type-2 diabetes

XIGDUO (dapagliflozin/metformin), antidiabetic - type-2 diabetes XIGDUO SUMMARY CT14263

Haute Autorite de sante2016

75. Once-Daily Liraglutide Versus Lixisenatide as Add-on to Metformin in Type 2 Diabetes: A 26-Week Randomized Controlled Clinical Trial

Once-Daily Liraglutide Versus Lixisenatide as Add-on to Metformin in Type 2 Diabetes: A 26-Week Randomized Controlled Clinical Trial 27311491 2016 08 24 2016 08 24 1935-5548 39 9 2016 Sep Diabetes care Diabetes Care Once-Daily Liraglutide Versus Lixisenatide as Add-on to Metformin in Type 2 Diabetes: A 26-Week Randomized Controlled Clinical Trial. 1501-9 10.2337/dc15-2479 To compare the efficacy and safety of liraglutide versus lixisenatide as add-on to metformin in patients (...) with type 2 diabetes not achieving adequate glycemic control on metformin alone. In this 26-week, randomized, parallel-group, open-label trial, 404 patients were randomized 1:1 to liraglutide 1.8 mg or lixisenatide 20 µg as add-on to metformin. Liraglutide was administered once daily at any time of the day. Lixisenatide was administered once daily within 1 h prior to the morning or evening meal. At week 26, liraglutide reduced HbA1c (primary end point) more than lixisenatide (estimated treatment difference -0.62

EvidenceUpdates2016

76. Metformin as prevention in people taking antipsychotic medication

Metformin as prevention in people taking antipsychotic medication Metformin as prevention in people taking antipsychotic medication » Morsels of Evidence Search Evidence based medicine for general practitioners « » Jun 14 Metformin as prevention in people taking antipsychotic medication Categories: , , , , by Journal reference: Zheng W, Li XB, Tang YL, Xiang YQ, Wang CY, de Leon J. Metformin for Weight Gain and Metabolic Abnormalities Associated With Antipsychotic Treatment: Meta-Analysis (...) of Randomized Placebo-Controlled Trials. J Clin Psychopharmacol 2015 Oct;35(5):499-509. Link: Published: October 2015 Evidence cookie says… The effect of metformin on cardiovascular disease in people living without diabetes on long-term antipsychotic medication is unknown. evidence exists on a number of surrogate endpoints that are CVD risks factors this evidence is heterogenous and its quality is not high metformin may have a small-to-moderate effect on weight gain Clinical scenario Ahmed, a 25-year-old

Morsels of Evidence2016

77. Durable response of glioblastoma to adjuvant therapy consisting of temozolomide and a weekly dose of AMD3100 (plerixafor), a CXCR4 inhibitor, together with lapatinib, metformin and niacinamide

Durable response of glioblastoma to adjuvant therapy consisting of temozolomide and a weekly dose of AMD3100 (plerixafor), a CXCR4 inhibitor, together with lapatinib, metformin and niacinamide 27489862 2016 08 04 2018 11 13 2331-4737 3 5-6 2016 Oncoscience Oncoscience Durable response of glioblastoma to adjuvant therapy consisting of temozolomide and a weekly dose of AMD3100 (plerixafor), a CXCR4 inhibitor, together with lapatinib, metformin and niacinamide. 156-63 10.18632/oncoscience.311

Oncoscience2016 Full Text: Link to full Text with Trip Pro

78. Efficacy and Safety of Titrated Canagliflozin in Patients With Type 2 Diabetes Mellitus Inadequately Controlled on Metformin and Sitagliptin

Efficacy and Safety of Titrated Canagliflozin in Patients With Type 2 Diabetes Mellitus Inadequately Controlled on Metformin and Sitagliptin 27160639 2016 07 13 2017 02 20 1463-1326 18 8 2016 Aug Diabetes, obesity & metabolism Diabetes Obes Metab Efficacy and safety of titrated canagliflozin in patients with type 2 diabetes mellitus inadequately controlled on metformin and sitagliptin. 812-9 10.1111/dom.12684 To evaluate the efficacy and safety of titrated canagliflozin, a sodium glucose co (...) -transporter 2 inhibitor, in patients with type 2 diabetes mellitus (T2DM) inadequately controlled on metformin and sitagliptin. In this randomized, double-blind study, patients with T2DM (N = 218) on metformin ≥1500 mg/day and sitagliptin 100 mg received canagliflozin 100 mg or placebo. After 6 weeks, the canagliflozin dose was increased from 100 to 300 mg (or from placebo to matching placebo) if all of the following criteria were met: baseline estimated glomerular filtration rate ≥70 ml/min/1.73 m(2

EvidenceUpdates2016 Full Text: Link to full Text with Trip Pro

79. Efficacy and safety of liraglutide versus sitagliptin, both in combination with metformin, in Chinese patients with type 2 diabetes: a 26-week, open-label, randomised, active comparator clinical trial

Efficacy and safety of liraglutide versus sitagliptin, both in combination with metformin, in Chinese patients with type 2 diabetes: a 26-week, open-label, randomised, active comparator clinical trial 27060930 2016 07 13 2017 02 20 1463-1326 18 8 2016 Aug Diabetes, obesity & metabolism Diabetes Obes Metab Efficacy and safety of liraglutide versus sitagliptin, both in combination with metformin, in Chinese patients with type 2 diabetes: a 26-week, open-label, randomized, active comparator (...) clinical trial. 803-11 10.1111/dom.12674 To compare the efficacy and safety of liraglutide versus sitagliptin as add-on to metformin after 26 weeks of treatment in Chinese patients with type 2 diabetes mellitus (T2DM). This 26-week open-label, active comparator trial (NCT02008682) randomized patients (aged 18-80 years) with T2DM inadequately controlled with metformin [glycated haemoglobin (HbA1c) 7.0-10.0% (53-86 mmol/mol)] 1 : 1 to once-daily subcutaneously administered liraglutide 1.8 mg (n = 184

EvidenceUpdates2016 Full Text: Link to full Text with Trip Pro

80. Empagliflozin and metformin (Synjardy)

Empagliflozin and metformin (Synjardy) Empagliflozin and metformin | CADTH.ca Find the information you need Empagliflozin and metformin Empagliflozin and metformin Last Updated: Result type: Reports Project Number: SR0489-000 Product Line: Generic Name: Empagliflozin and metformin Brand Name: Synjardy Manufacturer: Boehringer Ingelheim (Canada) Ltd. Indications: Diabetes mellitus (Type 2) Submission Type: New Project Status: Active Date Recommendation Issued: October 25, 2016 Recommendation

Canadian Agency for Drugs and Technologies in Health - Common Drug Review2016